Curium Buys Lantheus in Major Pharma Deal
Curium now owns Lantheus in a deal worth up to $8 billion, combining two big names in radioactive medicines.
Curium and Lantheus are joining forces. Curium bought its rival, Lantheus, for as much as $8 billion. This deal brings together two of the largest companies in radiopharmaceuticals. These companies make special drugs with radioactive parts. Doctors use these drugs to find and treat diseases like cancer.
Reports about this deal began months ago. Now, both companies confirm the purchase. This move changes the landscape of the radiopharma industry. It creates a much larger company with more power in the market.
The merger means more resources for research and development. It could lead to new ways to diagnose and fight serious illnesses. Patients may see new and better treatments in the future.
Source: FierceBiotech
More from Biotech
